Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Change in Accured Expenses (2020 - 2025)

Legend Biotech filings provide 6 years of Change in Accured Expenses readings, the most recent being $6.8 million for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 552.75% to $6.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$12.5 million, a 116.72% decrease, with the full-year FY2024 number at $45.7 million, up 3587.94% from a year prior.
  • Change in Accured Expenses hit $6.8 million in Q3 2025 for Legend Biotech, down from $20.9 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $77.0 million in Q4 2021 to a low of -$39.2 million in Q1 2023.
  • Median Change in Accured Expenses over the past 5 years was $7.4 million (2024), compared with a mean of $15.4 million.
  • Biggest five-year swings in Change in Accured Expenses: soared 1476.25% in 2023 and later crashed 623.51% in 2025.
  • Legend Biotech's Change in Accured Expenses stood at $77.0 million in 2021, then crashed by 97.73% to $1.7 million in 2022, then soared by 1476.25% to $27.5 million in 2023, then crashed by 105.36% to -$1.5 million in 2024, then skyrocketed by 558.97% to $6.8 million in 2025.
  • The last three reported values for Change in Accured Expenses were $6.8 million (Q3 2025), $20.9 million (Q2 2025), and -$38.6 million (Q1 2025) per Business Quant data.